title: Randomized controlled trials in maintenance of remission in Crohn's disease.
abstract: Maintenance of medically induced remission is a clinical challenge in Crohn's disease (CD), since it is a chronic disease and that often occurs in young people. The introduction of immunosuppressors and biologics has significantly improved the management of these patients, however efficacy and safety of these treatments in the very long term still needs clarification. Furthermore, scientific research is driven more into new drugs to induce remission rather then maintenance.
authors.affiliation: Department of Surgical, Oncological and Gastroenterological Sciences, Gastroenterology Unit, University of Padua, Italy.
authors.forename: Renata
authors.initials: R
authors.lastname: D'Incà
authors.forename: Roberta
authors.initials: R
authors.lastname: Caccaro
mesh_terms: D000068879:Adalimumab; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D003424:Crohn Disease / Q000178:diet therapy / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D012459:Salicylates / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D012459:Salicylates; D019819:Budesonide; D000069285:Infliximab; D000068879:Adalimumab; D008727:Methotrexate